Al-Ibraheem Akram, Abdlkadir Ahmed Saad, Juweid Malik E, Al-Rabi Kamal, Ma'koseh Mohammad, Abdel-Razeq Hikmat, Mansour Asem
Department of Nuclear Medicine and PET/CT, King Hussein Cancer Center, Al-Jubeiha, Amman 11941, Jordan.
Department of Radiology and Nuclear Medicine, Division of Nuclear Medicine, University of Jordan, Amman 11942, Jordan.
Cancers (Basel). 2023 Feb 7;15(4):1063. doi: 10.3390/cancers15041063.
Cancer immunotherapy has been extensively investigated in lymphoma over the last three decades. This new treatment modality is now established as a way to manage and maintain several stages and subtypes of lymphoma. The establishment of this novel therapy has necessitated the development of new imaging response criteria to evaluate and follow up with cancer patients. Several FDG PET/CT-based response criteria have emerged to address and encompass the various most commonly observed response patterns. Many of the proposed response criteria are currently being used to evaluate and predict responses. The purpose of this review is to address the efficacy and side effects of cancer immunotherapy and to correlate this with the proposed criteria and relevant patterns of FDG PET/CT in lymphoma immunotherapy as applicable. The latest updates and future prospects in lymphoma immunotherapy, as well as PET/CT potentials, will be discussed.
在过去三十年中，癌症免疫疗法在淋巴瘤领域得到了广泛研究。这种新的治疗方式现已成为管理和维持淋巴瘤多个阶段及亚型的一种方法。这种新型疗法的建立促使了新的成像反应标准的制定，以评估癌症患者并对其进行随访。基于氟代脱氧葡萄糖正电子发射断层显像/计算机断层扫描（FDG PET/CT）的几种反应标准已经出现，以应对和涵盖各种最常见的反应模式。目前，许多提议的反应标准正被用于评估和预测反应。本综述的目的是探讨癌症免疫疗法的疗效和副作用，并将其与淋巴瘤免疫疗法中适用的提议标准及FDG PET/CT的相关模式进行关联。还将讨论淋巴瘤免疫疗法的最新进展和未来前景，以及PET/CT的潜力。
Zotero 插件
